arrow
S

Shruti Gupta

Harvard Medical School
H指数:37
被引数:9,516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic biomarkers of kidney function in patients with newly diagnosed multiple myeloma receiving daratumumab-based combination therapy

新诊断多发性骨髓瘤患者接受达雷木单抗为基础联合治疗时肾功能的动态生物标志物

2026-11-150
PRE
Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis

空间转录组学及免疫检查点抑制剂相关间质性肾炎的机制

2026-09-010
PRE
eGFR Discordance and its Association with Outcomes following Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies

eGFR 不一致及其与异基因造血干细胞移植和过继性 T 细胞疗法后结局的关联

2026-04-010
PRE
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup

抗肿瘤疗法引起的肾毒性作用:第34届急性疾病质量倡议工作组共识报告

2025-12-080
OAAI
Nephrotoxicity of conventional chemotherapeutics: part 1-platinum compounds and antimetabolite agents

常规化疗药物的肾毒性:第一部分——铂类化合物和抗代谢剂

2025-12-010
PRE
Nephrotoxicity of conventional chemotherapeutics: part II-non-platinum agents and miscellaneous nephrotoxic drugs

常规化疗药物的肾毒性:第二部分——非铂类药物及其他肾毒性药物

2025-12-010
PRE
Urine Cell-Free RNA vs Plasma Cell-Free RNA for Monitoring of Kidney Injury and Immune Complications

尿液游离RNA与血浆游离RNA在肾脏损伤及免疫并发症监测中的比较

2025-08-010
OAAI
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor–associated acute interstitial nephritis

尿C-X-C基序配体9(CXCL9)在免疫检查点抑制剂相关急性间质性肾炎中的作用

2025-06-250
OAAI
Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology

免疫检查点抑制剂相关肾毒性的诊断与管理:美国肿瘤肾脏病学学会立场声明

2025-01-015
PRE
F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury

F18-FDG PET成像作为免疫检查点抑制剂相关急性肾损伤的诊断工具

2024-08-080
OAAI
Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology

评估癌症患者的肾小球滤过率: 美国肿瘤学会的声明

2024-06-071
PRE
Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies - Perspectives from the ASON

癌症患者GFR的评估第2部分: 抗癌治疗-ASON的观点

2024-06-070
OA
Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer
2024-04-222
OA
Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study

预测静脉注射顺铂后严重急性肾损伤的简单风险评分的推导和外部验证: 队列研究

2024-03-274
OAAI
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
2024-03-050
OAAI